Patient Safety First: Indian Regulator Takes Steps To Tighten Grip Over Site Inspections, Ensure Data Credibility
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - As India moves rapidly to become an integral part of large-scale global clinical trials, the Central Drugs Standard Control Organization under the Ministry of Health and Family Welfare has declared a set of new guidelines to ensure adequate safety of trial participants
You may also be interested in...
Pfizer, Lilly, Sanofi, Amgen And Others Named In Indian Clinical Trial Death Compensation Inquiry
The news of the health ministry probe earlier this month stirred debate about the gaping holes in Indian clinical trial laws and the country's loose enforcement framework, particularly as clinical trial projects flow rapidly into the country.
Pfizer, Lilly, Sanofi, Amgen And Others Named In Indian Clinical Trial Death Compensation Inquiry
The news of the health ministry probe earlier this month stirred debate about the gaping holes in Indian clinical trial laws and the country's loose enforcement framework, particularly as clinical trial projects flow rapidly into the country.
Pfizer, Lilly, Sanofi, Amgen And Others Implicated In Indian Clinical Trial Compensation Investigation; Are Ethics Committees To Blame?
MUMBAI - India's Health Ministry is calling on multinational drug companies operating in India - including Pfizer Inc., Eli Lilly & Co., Amgen Inc., Bristol-Myers Squibb Co., Boehringer Ingelheim GMBH, Sanofi, and Quintiles Transnational Corp. - to explain why they have not provided compensation to the families of 26 patients who died during clinical trials in the last year. A recent health ministry investigation found that out of 671 cases of reported deaths allegedly involving clinical trials - and involving as many as 44 companies - only three were compensated, but companies suggest regulators should look to India's ethics committees for answers